Short Interest in BeyondSpring Inc. (NASDAQ:BYSI) Decreases By 7.5%

BeyondSpring Inc. (NASDAQ:BYSIGet Rating) was the target of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 2,820,000 shares, a decline of 7.5% from the July 31st total of 3,050,000 shares. Approximately 13.2% of the company’s shares are sold short. Based on an average daily volume of 308,100 shares, the short-interest ratio is currently 9.2 days.

Hedge Funds Weigh In On BeyondSpring

Several hedge funds and other institutional investors have recently modified their holdings of BYSI. Fox Run Management L.L.C. bought a new position in shares of BeyondSpring during the fourth quarter valued at about $56,000. Alps Advisors Inc. bought a new position in shares of BeyondSpring during the fourth quarter valued at about $205,000. BNP Paribas Arbitrage SA raised its stake in shares of BeyondSpring by 2,749.1% during the fourth quarter. BNP Paribas Arbitrage SA now owns 109,890 shares of the company’s stock valued at $498,000 after acquiring an additional 106,033 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of BeyondSpring during the fourth quarter valued at about $83,000. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of BeyondSpring by 65.2% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 84,408 shares of the company’s stock valued at $186,000 after acquiring an additional 33,325 shares during the last quarter. 23.35% of the stock is owned by institutional investors.

BeyondSpring Price Performance

BeyondSpring stock opened at $1.27 on Friday. The company has a market capitalization of $49.44 million, a PE ratio of -0.77 and a beta of 1.04. The firm has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $1.76. BeyondSpring has a twelve month low of $1.13 and a twelve month high of $28.37.

About BeyondSpring

(Get Rating)

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.

See Also

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.